{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T22:27:34Z","timestamp":1786660054168,"version":"build-2736575974"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:00:00Z","timestamp":1781913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:00:00Z","timestamp":1781913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1038\/s41391-026-01131-6","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T13:39:20Z","timestamp":1781962760000},"page":"646-649","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of darolutamide plus androgen-deprivation therapy in Black patients with metastatic hormone-sensitive prostate cancer from the phase 3 ARANOTE trial"],"prefix":"10.1038","volume":"29","author":[{"given":"Quoc-Dien","family":"Trinh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0836-8542","authenticated-orcid":false,"given":"Daniel J.","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5767-0548","authenticated-orcid":false,"given":"Neal","family":"Shore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egils","family":"Vjaters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Olmos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Juliana P.","family":"de Santana Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4398-2708","authenticated-orcid":false,"given":"Augusto Cesar","family":"de Andrade Mota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Littleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankar","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Verholen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunhi Parambath","family":"Haresh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,20]]},"reference":[{"key":"1131_CR1","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75:10\u201345.","journal-title":"CA Cancer J Clin"},{"key":"1131_CR2","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1093\/oncolo\/oyab057","volume":"27","author":"MN Freeman","year":"2022","unstructured":"Freeman MN, Jang A, Zhu J, Sanati F, Nandagopal L, Ravindranathan D, et al. Multi-institutional analysis of the clinical and genomic characteristics of black patients with metastatic hormone-sensitive prostate cancer. Oncologist. 2022;27:220\u20137.","journal-title":"Oncologist"},{"key":"1131_CR3","doi-asserted-by":"publisher","first-page":"4271","DOI":"10.1200\/JCO-24-01798","volume":"42","author":"F Saad","year":"2024","unstructured":"Saad F, Vjaters E, Shore N, Olmos D, Xing N, Pereira de Santana Gomes AJ, et al. Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial. J Clin Oncol. 2024;42:4271\u201381.","journal-title":"J Clin Oncol"},{"key":"1131_CR4","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/oncolo\/oyad254","volume":"29","author":"ND Shore","year":"2024","unstructured":"Shore ND, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford D, et al. Efficacy and safety of darolutamide in combination with androgen-deprivation therapy and docetaxel in black patients from the randomized ARASENS trial. Oncologist. 2024;29:235\u201343.","journal-title":"Oncologist"},{"key":"1131_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","volume":"381","author":"KN Chi","year":"2019","unstructured":"Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;381:13\u201324.","journal-title":"N Engl J Med"},{"key":"1131_CR6","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, et al. ARCHES: A randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019;37:2974\u201386.","journal-title":"J Clin Oncol"},{"key":"1131_CR7","doi-asserted-by":"crossref","unstructured":"Saad F, Briganti A, Haresh KP, Vjaters E, Olmos D, Littleton N, et al. A deep prostate-specific antigen response to darolutamide plus androgen deprivation therapy is associated with better clinical outcomes in the phase 3 ARANOTE trial in patients with metastatic hormone-sensitive prostate cancer. Eur Urol Oncol. 2025;8:1321\u201332.","DOI":"10.1016\/j.euo.2025.06.010"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01131-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01131-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01131-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T21:44:48Z","timestamp":1786657488000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01131-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,20]]},"references-count":7,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1131"],"URL":"https:\/\/doi.org\/10.1038\/s41391-026-01131-6","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,20]]},"assertion":[{"value":"27 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Q-DT: Consulting: Astellas, Bayer, Intuitive Surgical, Janssen, Novartis, Pfizer; Research funding: American Cancer Society, Pfizer Global Medical Grants; Funding\/grants: Health Disparity Research Award from the Department of Defense Congressionally Directed Medical Research Program. DJG: Consulting: Bayer, Exelixis, Pfizer, Sanofi, Astellas Pharma, Innocrin Pharma, Bristol Myers Squibb, Genentech, Janssen, Merck Sharp & Dohme, Sumitomo Pharma America, (formerly Myovant Sciences), AstraZeneca, Michael J. Hennessy Associates, Constellation Pharmaceuticals, Physicians\u2019 Education Resource, Propella Therapeutics, RevHealth, Xcures, Novartis, Dendreon, Acerta, Calithera Biosciences. NS: Employment: AUC Specialists and START Cancer; Stock and other ownership interests: Photocure, Tutelix; Consulting\/Research: Bayer, Janssen Scientific Affairs, Dendreon, Ferring, Astellas, Amgen, Pfizer, AstraZeneca, Astellas Pharma, Merck, Bristol Myers Squibb\/ MDxHealth, Myriad Genetics, CG Oncology, UroGen Pharma, Clarity Pharmaceuticals, Lantheus Medical Imaging, Lilly, Telix Pharmaceuticals, Asieris Pharmaceuticals, Minomic, Novartis, Promaxo, Protara Therapeutics, Fize Medical, Accord Aura Biosciences, Bioprotect, Sumitomo. EV: Nothing to disclose. DO: Grants: AstraZeneca, Bayer, Janssen, Pfizer; Personal fees: AstraZeneca, Bayer, Clovis, Daiichi Sankyo, Janssen, Merck Sharp & Dohme, Pfizer; Non-financial support: Astellas Pharma, AstraZeneca, Bayer, F. Hoffman-LaRoche, Genentech, Ipsen, Janssen, Pfizer. AJPdSG: Invited speaker: Astellas, Bayer, Janssen, AstraZeneca; Advisory board member: Bayer, Janssen. ACdAM: Consulting: Astellas, AstraZeneca, Janssen, Pfizer; Research funding: Janssen, AstraZeneca, MSD, Merck, Nektar Therapeutics; Honoraria: Janssen, Pfizer; Advisory board member: Astellas, Bayer, Janssen, Pfizer. NL: Employment: Bayer. SS: Employment: Bayer. FV: Employment: Bayer. KPH: Nothing to disclose. FS: Consulting: AbbVie, Advanced Accelerator Applications, Astellas Pharma, AstraZeneca\/MedImmune, Bayer, GSK, Janssen Oncology, Myovant Sciences, Novartis, Pfizer, Knight Therapeautics, Sanofi, Sumitomo Dainippon Pharma Oncology, Tolmar; Honoraria: AbbVie, Advanced Accelerator Applications, Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, GSK, Janssen Oncology, Knight Therapeutics, Merck, Myovant Sciences, Novartis, Pfizer, Sanofi, Sumitomo Dainippon Pharma Oncology, Tolmar; Research funding to institution: AbbVie, Advanced Accelerator Applications, Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Janssen Oncology, Merck, Novartis, Pfizer, Point Therapeutics, Sanofi.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}